MARKET

DXCM

DXCM

Dexcom Inc
NASDAQ
65.49
+0.24
+0.37%
After Hours: 65.70 +0.21 +0.32% 19:02 12/05 EST
OPEN
65.38
PREV CLOSE
65.25
HIGH
66.75
LOW
65.15
VOLUME
3.85M
TURNOVER
--
52 WEEK HIGH
93.25
52 WEEK LOW
54.11
MARKET CAP
25.54B
P/E (TTM)
37.03
1D
5D
1M
3M
1Y
5Y
1D
DXCM Deadline: DXCM Investors with Losses in Excess of $100K Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
PR Newswire · 1d ago
Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025 - DXCM
PR Newswire · 1d ago
DexCom Faces Class Action Lawsuit Over Alleged Securities Fraud
Reuters · 1d ago
Health Rounds: Shingles vaccine reduces risk of death from dementia, study finds
Reuters · 1d ago
January 2026 Options Now Available For DexCom (DXCM)
NASDAQ · 2d ago
DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your Rights - DXCM
PR Newswire · 2d ago
LISTENING TO HEALTHCARE PROFESSIONALS: DEXCOM LAUNCHES NEW EDUCATION OFFERING, DEXCOM ACADEMY
Reuters · 2d ago
DexCom Inc. Faces Securities Fraud Class Action Lawsuit
Reuters · 3d ago
More
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.

Webull offers DexCom Inc stock information, including NASDAQ: DXCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DXCM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DXCM stock methods without spending real money on the virtual paper trading platform.